International survey identifies culture and leadership as central radiation oncology retention drivers
Across 53 countries, workforce retention was shaped by culture, leadership, career development, resource strain, recognition and burnout.
Across 53 countries, workforce retention was shaped by culture, leadership, career development, resource strain, recognition and burnout.
Across 27 years of COG trials, IMRT/VMAT replaced 3D photons while proton use expanded to nearly 40% of radiotherapy patients.
Unopposed progesterone use was associated with eightfold higher odds of tumor-related visual deficit among women referred for meningioma radiotherapy.
At ten years after prostate LDR brachytherapy, 85% of respondents remained satisfied, while bowel quality of life remained independently associated with satisfaction.
Tumor volume and OAR proximity drove brain metastasis fractionation, while preoperative SRS showed a substantial preference-to-practice gap.
Patients with clinician-documented fatigue had 39% lower odds of completing electronic fatigue assessments, exposing an important limitation of PRO-only monitoring.
Irradiating more than half of the axillary-lateral thoracic junction to 35 Gy was independently associated with a threefold higher lymphedema risk.
Modeling relationships between CT radiomic features improved distant-metastasis prediction over conventional radiomics across independent head and neck cancer cohorts.
Each 1-Gy increase in estimated immune-cell dose was associated with 66% higher breast cancer mortality after multivariable adjustment.
Administrative burden and staffing concerns were widespread, while reimbursement dominated private-practice concerns and unstable research funding dominated physician-scientist concerns.
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
In 201 recurrent glioblastomas, 80% required no more than 10.4 mm expansion to encompass 80% of recurrence volume.
Substantial physician-dependent dose variation meant treatment-group assignment did not consistently reflect the dose actually delivered to regional nodes.
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
Nearly 40% of visible internal mammary nodes regressed after chemotherapy, including 22% in patients without axillary nodal disease.